Longitudinal study of plasma biomarkers, in two independent cohorts, highlighted only p-tau217 as a surrogate marker of disease progression in early Alzheimer’s disease, supporting the development of new disease-modifying treatments.
- Nicholas J. Ashton
- Shorena Janelidze
- Oskar Hansson